drugset / Trial / NCT00069875

A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer

NCT00069875 ↗

Phase 2 Completed 195 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine and cisplatin in patients with non-small cell lung cancer.

Timeline

Start
2003-09
Primary completion
—
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ETALOCIB Small molecule — —
Background Cisplatin Other / unclassified — —
Background Gemcitabine Small molecule — —